Shares of Cassava Sciences (NASDAQ:SAVA), which has an Alzheimer’s drug candidate called simufilam, fell 35% on June 28 and another 13% over the weekend. This move in SAVA stock comes after a key science advisor was charged with defrauding the National Institutes of Health (NIH). Indeed, Hoau-Yan Wang, a professor at the City University of New York (CUNY), was charged with fraud of over $16 million in grants. Cassava opened today at about$10.70 per share, far from its June 28 opening price of nearly $19 pe ...